Research and Markets: The New Strategic Analysis Report Johnson & Johnson: Performance, Products, Pipeline and Potential, Provides a Complete and Critical Review of the Company.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c64668) has announced the addition of "Johnson & Johnson: Performance, Products, Pipeline and Potential" to their offering. Pharmaceutical company intelligence reports provide a full review of the company's activities together with five-year sales forecasts Sales forecast A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices ap·pen·di·ces n. A plural of appendix. provide more in-depth information on financials, agreements and corporate events. Johnson & Johnson, through more than 250 operating companies operating company A business that engages in transactions with outsiders. , manufactures and sells a broad range of products in the healthcare field for the pharmaceutical, consumer, and medical devices and diagnostic markets to most countries of the world. The company is organised on the principles of decentralised Adj. 1. decentralised - withdrawn from a center or place of concentration; especially having power or function dispersed from a central to local authorities; "a decentralized school administration" decentralized management, which gives the company a focus and a sense of ownership in local markets. J&J's major pharmaceutical growth drivers are Risperdal/Risperdal Consta, Topamax Topamax® Topiramate Neurology An agent used to manage partial seizures. See Epilepsy. , Concerta and Remicade. However, within our forecast period all of these products bar Remicade are predicted to experience significant sales declines related to patent expiries and generic competition. Other top selling products such as Duragesic, Procrit, Floxin, Levaquin and Aciphex are expected to report reduced sales by 2011. These threats to sales and growth have placed considerable pressure on J&J's pharmaceutical R&D efforts, although the company has had some recent developmental successes. In 2006, Prezista was launched, becoming J&J's first in-house developed anti-HIV compound. The company is placing increasing importance on virology virology, study of viruses and their role in disease. Many viruses, such as animal RNA viruses and viruses that infect bacteria, or bacteriophages, have become useful laboratory tools in genetic studies and in work on the cellular metabolic control of gene expression and Prezista will be J&J's flagship product A primary product of a company, which is typically why the company was founded and/or what made it well known. For example, MS-DOS, Windows and the Microsoft Office suite have been flagship products of Microsoft. CorelDRAW is a flagship product of Corel Corporation. as it moves into this relatively new area of interest. In addition, 2006 saw the launch of Dacogen for the treatment of myelodysplastic syndromes Myelodysplastic Syndrome Definition Myelodysplastic syndrome (MDS) is a disease that is associated with decreased production of blood cells. Blood cells are produced in the bone marrow, and the blood cells of people with MDS do not mature normally. . This product, alongside Velcade and Doxil, should help expand J&J's profile in the increasingly lucrative field of oncology oncology /on·col·o·gy/ (ong-kol´ah-je) the sum of knowledge regarding tumors; the study of tumors. on·col·o·gy n. . The most recent success in R&D was the launch of Invega in January 2007, for the treatment of schizophrenia The concept of a cure as such in the treatment of schizophrenia remains controversial, as there is no consensus on the definition of "treatment" in the case of schizophrenia, although some criteria for the remission of symptoms have recently been suggested. . J&J's current top-selling product is the Risperdal/Risperdal Consta franchise, also used in the treatment of schizophrenia. Patent protection for Risperdal expires in June 2008, and consequently, the company will hope Invega can become a long-term replacement as Risperdal becomes increasingly less profitable. Historically, the Consumer segment has been the smallest of J&J's three core businesses. However, in December 2006, the company completed the acquisition of Pfizer's Consumer Healthcare Business for US$17 billion. This purchase should see the Consumer segment compete more effectively with Medical Devices and Diagnostics and Pharmaceuticals. Within Pharmaceuticals, J&J can expect a difficult transition period as older, non-patented products, are replaced with new compounds. The bolstering of the Consumer segment should help overshadow o·ver·shad·ow tr.v. o·ver·shad·owed, o·ver·shad·ow·ing, o·ver·shad·ows 1. To cast a shadow over; darken or obscure. 2. To make insignificant by comparison; dominate. these difficulties in the short-term, and J&J has both in its pipeline, and in its most recent product launches, the assets to achieve growth and strong sales in the medium- to long-term. This new strategic analysis report Johnson & Johnson: Performance, Products, Pipeline and Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. The report is updated on a quarterly basis. Buyers of the web edition receive quarterly reports for a year. Buyers of the print/pdf editions receive the latest version. All formats are the same price. For more information, visit http://www.researchandmarkets.com/reports/c64668 Source: Espicom |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion